The historical rank and industry rank for Valerio Therapeutics's FCF Margin % or its related term are showing as below:
XPAR:ALVIO'
s FCF Margin % Range Over the Past 10 Years
Min: -976.33 Med: -284.16 Max: 20.25
Current: 20.25
During the past 13 years, the highest FCF Margin % of Valerio Therapeutics was 20.25%. The lowest was -976.33%. And the median was -284.16%.
XPAR:ALVIO's FCF Margin % is ranked better than 89.27% of 951
companies
in the Biotechnology industry
Industry Median: -82.65
vs XPAR:ALVIO: 20.25
Valerio Therapeutics FCF Margin % Related Terms
Valerio Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Valerio Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALVIO vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Valerio Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valerio Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Valerio Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valerio Therapeutics (XPAR:ALVIO) has a FCF Margin % of 172.86% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Valerio Therapeutics and its competitors. According to the industry distribution chart, Valerio Therapeutics ranks #102 out of 951 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Valerio Therapeutics' FCF Margin % too high?
Valerio Therapeutics' current FCF Margin % is 172.86%. Based on the distribution chart, Valerio Therapeutics ranks #102 out of 951 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valerio Therapeutics has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valerio Therapeutics ranks #102 out of 951 companies for FCF Margin %. This places Valerio Therapeutics in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Valerio Therapeutics and its competitors. Valerio Therapeutics's current FCF Margin % is 172.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.51 — trading 628.6% above its estimated fair value. The current FCF Margin % is 172.86%. Valerio Therapeutics' overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current FCF Margin % is 172.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?
Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued.
The current stock price of €0.51 is trading 628.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.
Key valuation signals for XPAR:ALVIO:
FCF Margin %: 172.86%
GF Value™: €0.07 vs. price of €0.51 (628.6% above fair value)
No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
25GF Score
Get the complete analysis for XPAR:ALVIO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVIO has been successfully added to your 
